Literature DB >> 23531071

Western blot patterns of serum autoantibodies against optic nerve antigens in dogs with goniodysgenesis-related glaucoma.

Stephanie A Pumphrey1, Stefano Pizzirani, Christopher G Pirie, M Sawkat Anwer, Tanya Logvinenko.   

Abstract

OBJECTIVE: To investigate whether differences existed between clinically normal dogs and dogs with goniodysgenesis-related glaucoma (GDRG) in serum autoantibodies against optic nerve antigens. ANIMALS: 16 dogs with GDRG, 17 healthy dogs with unremarkable pectinate ligament and iridocorneal angle morphology, and 13 euthanized dogs with no major ocular abnormalities or underlying diseases. PROCEDURES: Western blotting was performed with optic nerve extracts from the euthanized dogs as an antigen source and serum from clinically normal dogs and dogs with GDRG as a primary antibody (autoantibody) source. Blots were evaluated for presence and density of bands.
RESULTS: Multiple bands were identified on western blots from all dogs with GDRG and all clinically normal dogs, with a high degree of variability among individual dogs. Dogs with GDRG were significantly more likely than healthy dogs to have bands present at 38, 40, and 68 kDa. Dogs with GDRG had significant increases in autoreactivity at 40 and 53 kDa and a significant decrease in autoreactivity at 48 kDa. CONCLUSIONS AND CLINICAL RELEVANCE: Significant differences in serum autoantibodies against optic nerve antigens were found in dogs with versus without GDRG. Although it remains unclear whether these differences were part of the pathogenesis of disease or were sequelae to glaucomatous changes, these findings provide support for the hypothesis that immune-mediated mechanisms play a role in the development or progression of GDRG. However, the high degree of variability among individual dogs and the considerable overlap between groups suggest that the clinical usefulness of this technique for distinguishing dogs with GDRG from clinically normal dogs is likely limited.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23531071      PMCID: PMC4048013          DOI: 10.2460/ajvr.74.4.621

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  60 in total

1.  Evaluation of canine serum for the presence of antiretinal autoantibodies in sudden acquired retinal degeneration syndrome.

Authors:  Rachel L Keller; Stephen A Kania; Diane V H Hendrix; Daniel A Ward; Kenneth Abrams
Journal:  Vet Ophthalmol       Date:  2006 May-Jun       Impact factor: 1.644

Review 2.  Autoimmune basis of glaucoma.

Authors:  Tarek A Shazly; Mouhab Aljajeh; Mark A Latina
Journal:  Semin Ophthalmol       Date:  2011 Jul-Sep       Impact factor: 1.975

3.  Serum autoantibodies to alpha-fodrin are present in glaucoma patients from Germany and the United States.

Authors:  Franz H Grus; Stephanie C Joachim; Kai Bruns; Karl J Lackner; Norbert Pfeiffer; Martin B Wax
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-03       Impact factor: 4.799

4.  Antiphosphatidylserine antibodies are elevated in normal tension glaucoma.

Authors:  S Kremmer; E Kreuzfelder; R Klein; N Bontke; K B Henneberg-Quester; K P Steuhl; H Grosse-Wilde
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

5.  Enhanced characterization of serum autoantibody reactivity following HSP 60 immunization in a rat model of experimental autoimmune glaucoma.

Authors:  S C Joachim; M B Wax; P Seidel; N Pfeiffer; F H Grus
Journal:  Curr Eye Res       Date:  2010-10       Impact factor: 2.424

6.  Valosin-containing protein is a novel autoantigen in patients with glaucoma.

Authors:  Koon-Ja Lee; Seon-Mi Jeong; Benjamin Douglass Hoehn; Young Jae Hong; Sung Ho Lee
Journal:  Optom Vis Sci       Date:  2011-01       Impact factor: 1.973

7.  Selective impairment of serum antibody repertoires toward muscle and thymus antigens in patients with seronegative and seropositive myasthenia gravis.

Authors:  T Sharshar; S Lacroix-Desmazes; L Mouthon; S Kaveri; P Gajdos; M D Kazatchkine
Journal:  Eur J Immunol       Date:  1998-08       Impact factor: 5.532

8.  Retrograde axonal transport obstruction of brain-derived neurotrophic factor (BDNF) and its TrkB receptor in the retina and optic nerve of American Cocker Spaniel dogs with spontaneous glaucoma.

Authors:  Simone Iwabe; Norma A Moreno-Mendoza; Francisco Trigo-Tavera; Cheryl Crowder; Gustavo A García-Sánchez
Journal:  Vet Ophthalmol       Date:  2007 Nov-Dec       Impact factor: 1.644

Review 9.  Normal-tension glaucoma: is it different from primary open-angle glaucoma?

Authors:  M Bruce Shields
Journal:  Curr Opin Ophthalmol       Date:  2008-03       Impact factor: 3.761

10.  GpnmbR150X allele must be present in bone marrow derived cells to mediate DBA/2J glaucoma.

Authors:  Michael G Anderson; K Saidas Nair; Leslie A Amonoo; Adrienne Mehalow; Colleen M Trantow; Sharmila Masli; Simon W M John
Journal:  BMC Genet       Date:  2008-04-10       Impact factor: 2.797

View more
  4 in total

Review 1.  Biomechanics of the optic nerve head and sclera in canine glaucoma: A brief review.

Authors:  Shin Ae Park; András M Komáromy
Journal:  Vet Ophthalmol       Date:  2021-08-17       Impact factor: 1.644

Review 2.  Looking into the future: Gene and cell therapies for glaucoma.

Authors:  András M Komáromy; Kristin L Koehl; Shin Ae Park
Journal:  Vet Ophthalmol       Date:  2021-01-07       Impact factor: 1.644

3.  Primary closed angle glaucoma in the Basset Hound: Genetic investigations using genome-wide association and RNA sequencing strategies.

Authors:  James A C Oliver; Sally L Ricketts; Markus H Kuehn; Cathryn S Mellersh
Journal:  Mol Vis       Date:  2019-02-08       Impact factor: 2.367

Review 4.  The future of canine glaucoma therapy.

Authors:  András M Komáromy; Dineli Bras; Douglas W Esson; Ronald L Fellman; Sinisa D Grozdanic; Larry Kagemann; Paul E Miller; Sayoko E Moroi; Caryn E Plummer; John S Sapienza; Eric S Storey; Leandro B Teixeira; Carol B Toris; Terah R Webb
Journal:  Vet Ophthalmol       Date:  2019-05-20       Impact factor: 1.644

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.